Viral Vector Manufacturing Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-26　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 3,874.6 Mn
2033 年預估規模: USD 8,829.1 Mn
年複合成長率 CAGR: 17.6%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-26頁數 168報告編號 CMI9396

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Viral Vector Manufacturing Market, By Workflow (Downstream Manufacturing (Purification and Fill Finish) and Upstream Manufacturing (Vector Amplification, Editing and Expansion, and Vector Recovery/Harvesting)), By Type (Adeno-associated viruses (AAVs), Lentiviruses, Retroviruses, Adenoviruses, and Others), By Product & Services (Product and Services), By Application (Cell and Gene Therapy, Vaccine Development, and Research), By Disease Indication (Cancer, Generic Disorders, Infectious Diseases, and Others), By End User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

The global viral vector manufacturing market is estimated to be valued at USD 3,874.6 Mn in 2026 and is expected to reach USD 8,829.1 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 17.6% from 2026 to 2033. The global viral vector manufacturing market represents a critical component of the modern biotechnology and pharmaceutical landscape, serving as the backbone for advanced gene and cell therapy development. Viral vectors are genetically modified viruses engineered to deliver therapeutic genes into target cells, making them indispensable tools in treating genetic disorders, cancers, and various other diseases. The manufacturing of these sophisticated biological products requires specialized facilities, advanced technologies, and stringent quality control measures to ensure safety and efficacy. As the gene therapy sector experiences unprecedented growth, driven by breakthrough treatments and regulatory approvals, the demand for high-quality viral vector manufacturing services has surged dramatically. The market encompasses various vector types including lentiviral, retroviral, adenoviral, and adeno-associated virus (AAV) vectors, each requiring distinct manufacturing processes and expertise. Contract development and manufacturing organizations (CDMOs) play a pivotal role in this ecosystem, providing essential services to biotechnology companies and pharmaceutical giants alike. The complexity of viral vector production, combined with significant capital requirements and regulatory compliance demands, has created a specialized market segment that continues to evolve rapidly with technological advancements and increasing therapeutic applications. Market Dynamics The global viral vector manufacturing market is primarily driven by the exponential growth in gene and cell therapy approvals, with regulatory agencies worldwide demonstrating increased acceptance of these innovative treatments. The rising prevalence of genetic disorders, cancer, and rare diseases has created substantial demand for personalized medicine solutions, positioning viral vectors as essential delivery mechanisms for therapeutic genes. Significant investments in research and development by pharmaceutical companies, coupled with venture capital funding for biotechnology startups, have accelerated market expansion. However, the market faces considerable restraints including the extremely high manufacturing costs associated with viral vector production, complex regulatory requirements that vary across different regions, and technical challenges related to scalability and yield optimization. The shortage of specialized manufacturing facilities and skilled workforce further constrains market growth, as companies struggle to meet increasing demand while maintaining quality standards. Supply chain complexities and lengthy development timelines also pose significant barriers to market entry. Nevertheless, substantial opportunities exist through technological advancements in manufacturing processes, including the development of suspension cell culture systems, single-use bioreactors, and automated production platforms that promise to reduce costs and improve efficiency. The expanding pipeline of gene therapies targeting various therapeutic areas presents lucrative growth prospects, while emerging markets offer untapped potential for market expansion. Strategic partnerships between biotechnology companies and established CDMOs are creating synergistic opportunities, enabling faster market access and risk mitigation. Additionally, increasing government support through funding initiatives and favorable regulatory frameworks is expected to further stimulate market growth. Key Features of the Study • This report provides in-depth analysis of the global viral vector manufacturing market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global viral vector manufacturing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, FUJIFILM Diosynth Biotechnologies, Merck KGaA, AGC Biologics, Charles River Laboratories, Oxford Biomedica, Viralgen, Minaris Advanced Therapies, WuXi Advanced Therapies, SK pharmteco, Resilience, uniQure, and Novartis Gene Therapies • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global viral vector manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector manufacturing market Market Segmentation • Workflow Insights (Revenue, USD Mn, 2021 - 2033) o Downstream Manufacturing  Purification  Fill Finish o Upstream Manufacturing  Vector Amplification, Editing and Expansion  Vector Recovery/Harvesting • Type Insights (Revenue, USD Mn, 2021 - 2033) o Adeno-associated viruses (AAVs) o Lentiviruses o Retroviruses o Adenoviruses o Others • Product & Services Insights (Revenue, USD Mn, 2021 - 2033) o Product o Services • Application Insights (Revenue, USD Mn, 2021 - 2033) o Cell and Gene Therapy o Vaccine Development o Research • Disease Indication Insights (Revenue, USD Mn, 2021 - 2033) o Cancer o Generic Disorders o Infectious Diseases o Others • End User Insights (Revenue, USD Mn, 2021 - 2033) o Pharmaceutical and Biopharmaceutical Companies o Academics and Research Institutes o Others • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Lonza o Catalent o Thermo Fisher Scientific o FUJIFILM Diosynth Biotechnologies o Merck KGaA o AGC Biologics o Charles River Laboratories o Oxford Biomedica o Viralgen o Minaris Advanced Therapies o WuXi Advanced Therapies o SK pharmteco o Resilience o uniQure o Novartis Gene Therapies

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Viral Vector Manufacturing Market, By Workflow  Global Viral Vector Manufacturing Market, By Type  Global Viral Vector Manufacturing Market, By Product & Services  Global Viral Vector Manufacturing Market, By Application  Global Viral Vector Manufacturing Market, By Disease Indication  Global Viral Vector Manufacturing Market, By End User  Global Viral Vector Manufacturing Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Viral Vector Manufacturing Market, By Workflow, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Downstream Manufacturing  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Purification o Fill Finish o Upstream Manufacturing  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Vector Amplification, Editing and Expansion o Vector Recovery/Harvesting 5. Global Viral Vector Manufacturing Market, By Type, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Adeno-associated viruses (AAVs)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Lentiviruses  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Retroviruses  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Adenoviruses  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Viral Vector Manufacturing Market, By Product & Services, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Product  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Services  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Viral Vector Manufacturing Market, By Application, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cell and Gene Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Vaccine Development  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Research  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 8. Global Viral Vector Manufacturing Market, By Disease Indication, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Generic Disorders  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Infectious Diseases  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 9. Global Viral Vector Manufacturing Market, By End User, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Pharmaceutical and Biopharmaceutical Companies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Academics and Research Institutes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 10. Global Viral Vector Manufacturing Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Workflow, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Product & Services, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Disease Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 11. Competitive Landscape o Lonza  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Catalent  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Thermo Fisher Scientific  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o FUJIFILM Diosynth Biotechnologies  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck KGaA  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AGC Biologics  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Charles River Laboratories  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Oxford Biomedica  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Viralgen  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Minaris Advanced Therapies  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o WuXi Advanced Therapies  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o SK pharmteco  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Resilience  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o uniQure  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis Gene Therapies  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 12. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 13. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'Viral Vector Manufacturing Market' - Global forecast to 2033

提及公司

LonzaCatalentThermo Fisher ScientificFUJIFILM Diosynth BiotechnologiesMerck KGaAAGC BiologicsCharles River LaboratoriesOxford BiomedicaViralgenMinaris Advanced TherapiesWuXi Advanced TherapiesSK pharmtecoResilienceuniQureNovartis Gene Therapies

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們